Docket No.: PB60713

Serial No.

Filing Date

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

for wh	nich a patent is	sought on the invention	on entitled:			
"BEN	"BENZIMIDAZOL SUBSTITUTED THIOPENE DERIVATIVES WITH ACTIVITY ON IKK3"					
the sp	is attached he	07 February 2005		PCT/EP2005/001432 plicable).		
I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above.						
I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.						
I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.						
	Foreign Applica	- · ·				
Number 040280		Country Great Britain	Filing Date 09 February 2004	Priority Claimed YES		
I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below. Application Number Filing Date						
търпо	ation ivalliber	Timig Date				
applic listed disclo- first pa inform Sectio	ation(s) or Sect below and, inso sed in the prior aragraph of Titl nation which is n 1.56 which be	ion 365(c) of any PC of ar as the subject mat United States or PCT le 35, United States C material to patentabil	T International applicate ter of each of the claim International applicatione, Section 112, I ack ity as defined in Title 3 een the filing date of the	ction 120 of any United States cion designating the United State as of this application is not on in the manner provided by the nowledge the duty to disclose 37, Code of Federal Regulations are prior application and the	ne	

Status

Direct all correspondence to the address associated with Customer Number 20462.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Paul BAMBOROUGH

Inventor's Signature: Paul bandora

Date: 16 Sept 2005

Residence: Stevenage, Hertfordshire, GB

Citizenship: British

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: James Vaughan MOREY

Inventor's Signature:

Residence:

c/o Stevenage, Hertfordshire, GB

Citizenship: British

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

PLEASE ACKNOWLEDGE YOUR UNDERSTANDING OF THIS DOCUMENT BY SIGNING THIS SHEET WHERE INDICATED BELOW AND RETURN IT TO ME.

To: Paul Bamborough

James Morey

Stephanie Learoyd From:

PB60713 Re:

EXECUTION OF APPLICATION FOR UNITED STATES PATENT

Enclosed is an application for United States patent including a Declaration for your signature which is required by the United States Patent and Trademark Office. The statements in the Declaration include the following:

- you believe that you are the first inventor or joint inventor of the claimed invention; (a)
- (b) you have reviewed and understand the contents of the patent application; and
- (c) you acknowledge the duty to disclose information material to the patentability of the invention.

Further, it is a requirement under the law and the Rules of the Patent and Trademark Office that the "best mode" for carrying out the invention known to you at the present time must be disclosed. For example, for a new series of compounds, the best route of synthesis which you know of must be disclosed. Any biological data should be a fair representation of all the data obtained to date.

Please review the specification, claims, and declaration carefully, keeping in mind your obligations as set forth above. The statements and descriptions in the specification should be true and accurate to the best of your knowledge. Generally, minor typographical errors can be corrected by amendment after filing the application. Any other errors or omissions you might find should be discussed with me by telephone prior to executing the application. Do not make any marks on the application. Once you are satisfied that the entire application is accurate and complete, please sign and date the Declaration and return the signed and dated Declaration and the accompanying specification to me.

If any material references or chemical or biological data relating to this application are available to you which have not been communicated to me, please do so immediately.

Should you receive the documentation in electronic format and be asked to print out the documents prior to signing, please ensure the following:

- that the documents are printed in single sided format
- that they are printed in black and white, and not colour
- that they are not hole punched

If you have any questions, please contact the indicated attorney or agent.

Paul BAMBOROUGH

Date 16th Sept 2005